FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 688 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Deaths from Metastatic Melanoma Drop Substantially in the United States April 21, 2020 Determination of the Incidence of Driver Mutations in Patients with NSCLC... March 24, 2021 Preclinical Study May Have Found New Treatment Option for Triple-Negative Breast... June 8, 2021 ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large... April 16, 2015 Load more HOT NEWS Teacher’s Mental Health Check-In Board Goes Viral For The ‘Beautiful’ Standard... Teacher Visits Student Battling Cancer At Home To Help With His... Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast... How My Navy Career Helped Shape My Positive Attitude During My...
